Abstract: A polypeptide of the formula (SEQ ID NO 24): X-Glu-Thr-Gly-Gln-Glu-Thr-Ala-Tyr-Phe-Ile-Leu-Lys-Leu-Ala-Gly-Arg-Trp-Pro- Val-Lys-Z wherein X is a chain of from 1 to 20 amino acid residues or an amino-terminal group and Z is a chain of from 1 to 20 amino acid residues or a carboxy-terminal group. The polypeptide immunologically mimics HIV endonuclease (p 31).
Abstract: The invention concerns peptides which react immunochemically with antibodies directed against NANBH. A method for the detection of NANBH or anti-NANBH in a test fluid, an immunochemical reagent and a testkit to be used when applying said detection methods belong to the invention.
Type:
Grant
Filed:
March 28, 1991
Date of Patent:
July 20, 1993
Assignee:
AKZO NV
Inventors:
Winand J. A. Habets, Terukatsu Arima, Pieter J. Boender
Abstract: This invention provides a purified endotoxin-induced thrombosis factor, preferably an endotoxin-induced thrombosis factor characterized by an apparent molecular weight between about 50,000 and 65,000 daltons, more specifically about 55,000 daltons, on reduced and nonreduced SDS-polyacrylamide gels, by maximal recovery on elution from such gels at 52,000 to 58,000 daltons, by the ability to migrate as a single band on such gels, by the ability to precipitate in ammonium sulfate at saturations from 40% to 70%, by the ability to precipitate in polyethylene glycol at concentrations above 15%, by high hydrophobicity, by the ability to bind weakly to a hydroxylapatite column and to a lentil lectin column, by the ability to bind tightly to a hydrophobic interaction resin and smear off with ethylene glycol, and by the ability to bind tightly to a reverse-phase column and elute more effectively with isopropranol than with acetonitrile, by the ability to bind to an anion exchange resin over a pH range from 5 to 10, by
Type:
Grant
Filed:
February 28, 1990
Date of Patent:
July 13, 1993
Assignee:
The Trustees of Columbia University in the City of New York
Abstract: Tripeptides having general formula II Glu-Lys-Arg in which: Glu is a glutamic acid residue, Lys is a lysine residue and Arg is an arginine residue are described. The aminoacids composing the tripeptides of the invention may be either of the natural, L-series or of the D-series or a racemic mixture of the two said series, but the aminoacids are preferably selected from the L-forms even though D- or DL aminoacids may also be considered. The invention refers also to the process for the preparation of said peptides as well as to their use as immunostimulant agents.
Abstract: A method to obtain selected individual peptides or families thereof which have a target property and optionally to determine the amino acid sequence of a selected peptide or peptides to permit synthesis in practical quantities is disclosed. In general outline, the method of the invention comprises synthesizing a mixture of randomly or deliberately generated peptides using standard synthesis techniques, but adjusting the individual concentrations of the components of a mixture of sequentially added amino acids according to the coupling constants for each amino acid/amino acid coupling. The subgroup of peptides having the target property can then be selected, and either each peptide isolated and sequenced, or analysis performed on the mixture to permit its composition to be reproduced. Also included in the invention is an efficient method to determine the relevant coupling constants.
Type:
Grant
Filed:
March 22, 1991
Date of Patent:
July 6, 1993
Assignee:
The Regents of the University of California
Abstract: A dodecapeptide for regulating weight gain in mammals, as defined in the sequence:CHHRKKGYADLYwherein C is cysteine, H is histidine, R is arginine, K is lysine, G is glycine, Y is tyrosine, A is alanine, D is aspartic acid and L is leucine; and the remaining amino acids are each independently glycine, alanine, valine, leucine, isoleucine, serine, threonine, cysteine, cystine, methionine, aspartic acid, glutamic acid, asparagine, glutamine, lysine hydroxylysine, histidine, arginine, phenylalanine, tyrosine, tryptophan, proline or hydroxyproline.
Abstract: Presented are an oxidized-type glutathione alkyl ester represented by the formula (I). ##STR1## wherein R denotes a lower alkyl group, and a salt thereof: a method of preparing said ester which is comprised of oxidizing a reduced-type glutathione monoalkyl ester represented by the formula (II), ##STR2## wherein R is as defined above, with the air, hydrogen peroxide or iodine in an aqueous solution: and a pharmaceutical composition and method for suppression of hepatic disorders characterized in that it contains as an active constituent said ester or a pharmaceutically acceptable salt thereof.
Abstract: The invention concerns novel renin-inhibitory compounds which are useful for treating renin-associated hypertension, congestive heart failure, hyperaldosteronism, glaucoma, and diseases caused by retroviruses including HTLV-I -II, and -III. Processes for preparing the compounds, novel intermediates useful in the preparation thereof, compositions containing them, and methods of using them are included. Also included is a diagnostic method which uses the compounds to determine the presence of renin-associated hypertension, congestive heart failure, or hyperaldosteronism.
Abstract: Hydrophilic organic colloids such as collagen or gelatin are modified for use in photographic elements such as film or paper, or for use as reagents in automated dry chemical analyzers. The modification comprises reaction of some of the carboxy groups attached to the polypeptide with (i) a amide bond forming agent, e.g. 1-pyrrolidinylcarbonylpyridinium chloride, and (ii) a di- or triamine, such as piperazine, diethylenetriamine or ethylenediamine. Such modification enables that colloid to react faster with a gelatin hardener such as bis(vinylsulfonyl)methane (BVSM). When coated over an equal amount of unmodified gelatin, and both layers imbibed with BVSM, a modified gelatin layer showed an enzyme resistance greater than that of the unmodified gelatin. This demonstrates that the modified gelatin hardened preferentially.
Abstract: The present invention relates to a peptide encoding an antagonist of VIP. The invention also relates to a method of using said peptide to antagonize VIP function. The invention further relates to a pharmaceutical composition.
Type:
Grant
Filed:
November 30, 1990
Date of Patent:
June 8, 1993
Assignee:
The United States of America as represented by the Secretary of the Department of Health & Human Services
Inventors:
Illana Gozes, Douglas E. Brenneman, Mati M. Fridkin, Terry Moody
Abstract: The present invention provides substituted cyclic tetrapeptide compounds of Formula I: ##STR1## and the pharmaceutically acceptable salts, esters and amides thereof, which are useful for treating pain in animals, pharmaceutical compositions which comprises a therapeutically-effective amount of a compound of Formula I in combination with a pharmaceutically-acceptable carrier, and a method for eliminating or ameliorating pain in an animal comprising administering a therapeutically-effective amount of a compound of Formula I to the animal.
Type:
Grant
Filed:
May 21, 1991
Date of Patent:
June 1, 1993
Assignee:
G. D. Searle & Co.
Inventors:
Donald W. Hansen, Jr., Karen B. Peterson, Nizal S. Chandrakumar, Henry I. Mosberg
Abstract: A process for producing an amide or an ester represented by the general formula W-A-B-Y which involves reacting an ester sulfonium salt represented by the general formula: ##STR1## with a nucleophilic agent represented by the general formulaH--B--Ywherein B represents a nucleophilic group, and wherein the members of the formula are further described in detail in the specification.
Abstract: Novel amino acid derivatives of the formula IX--Z--NH--CHR.sup.1 --CO--NR.sup.2 --CHR.sup.3 --CR.sup.4 --(CHR.sup.5).sub.n --CO--E--W'--Ywherein X, Z, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, E, W', Y and n have the meanings defined herein and their salts inhibit the activity of human plasma renin.
Type:
Grant
Filed:
November 27, 1987
Date of Patent:
June 1, 1993
Assignee:
Merck Patent Gesellschaft mit Beschrankter Haftung
Inventors:
Gunter Holzemann, Peter Raddatz, Claus J. Schmitges, Klaus Otto Minck, Alfred Jonczyk, Johannes Sombroek, Joachim Gante
Abstract: New amino acid derivatives of the formulaR.sup.1 --Z--NR.sup.2 --CHR.sup.3 --CR.sup.4 --(CHR.sup.5).sub.a --CO--E--Q--Ywherein R.sup.1 to R.sup.5, a, Z, E, Q and Y have the meanings defined herein, and salts thereof inhibit the activity of human plasma renin.
Type:
Grant
Filed:
November 30, 1989
Date of Patent:
June 1, 1993
Assignee:
Merck Patent Gesellschaft mit beschrankter Haftung
Inventors:
Joachim Gante, Peter Raddatz, Johannes Sombroek, Claus J. Schmitges, Klaus O. Minck
Abstract: A polyethylene glycol derivative of the formula ##STR1## wherein R represents a lower alkyl and n represents an optional positive integer which renders the average molecular weight of the polyethylene glycol moiety about 1,000 to 12,000, a peptide modified by said polyethylene glycol derivative and a method for production thereof. The polyethylene glycol derivative (I) is capable of modifying the guanidino groups in peptides. The peptides modified by the polyethylene glycol derivative (I) are extremely stable, are considerably delayed in biological clearance (i.e. the durability is extended) and exhibit their physiological activities effectively over the long period.
Abstract: Methods, compounds and compositions are provided for inducing natriuresis, diuresis and vasodilatation in mammalian hosts by administering atrial natriuretic/vasodilator peptides to said host. Also provided are methods for producing such peptide compounds.
Type:
Grant
Filed:
June 5, 1986
Date of Patent:
May 18, 1993
Assignee:
Scios Nova Inc.
Inventors:
John A. Lewicki, Robert M. Scarborough, Jr.
Abstract: In a process for the solid phase synthesis of a polypeptide containing at least one serine residue, the improvement comprising temporarily protecting the side chain of the serine residue with a protecting group which is removed immediately following the addition of the serine to the peptide chain.
Type:
Grant
Filed:
February 8, 1991
Date of Patent:
May 18, 1993
Assignee:
Syntex (U.S.A.) Inc.
Inventors:
John J. Nestor, Jr., Natalie L. McClure, Humberto Arzeno
Abstract: This invention is directed to peptide fragments of porcine somatotropin (pST) which are used to generate epitope-specific anti-pST antibodies. When such antibodies are administered with pST to warm-blooded animals, the growth enhancing activity of pST is potentiated.
Type:
Grant
Filed:
October 27, 1989
Date of Patent:
May 11, 1993
Assignee:
American Cyanamid Company
Inventors:
Bosco S. Wang, Ian C. Hart, Hong-Ming Shieh